Wolleschak D, Mack TS, Perner F, Frey S, Schnöder TM, Wagner M-C, Höding C, Pils MC, Parkner A, Kliche S, Schraven B, Hebel K, Brunner-Weinzierl M, Ranjan S, Isermann B, Lipka DB, Fischer T, Heidel FH. Clinically relevant doses of FLT3-kinase inhibitors quizartinib and midostaurin do not impair T-cell reactivity and function. Haematologica [Internet]. 2014May31 [cited 2026Nov.3];99(6):e90-e93. Available from: https://haematologica.org/article/view/7069